Daewoong Pharmaceutical and Hanall Biopharma announced that they had made a joint investment worth $1 million in Alloplex Biotherapeutics, a Boston-based drug development company. The two companies plan to work together to develop Alloplex’s anti-cancer immune cell treatment.
To request interviews, high res images or other materials, media are asked to:
Email: media@alloplexbio.com
Attn: Lesley White, Alloplex Australia
For media requests on deadline during USA Eastern hours, please call: +1-781-281-2013
